

# INVITATION



**WEDNESDAY,  
13 AUGUST 2025**

📍 19:00 – 20:00 (SYD/MELB/CAN)  
📍 18:30 – 19:30 (ADELAIDE)

📍 19:00 – 20:00 (BRISBANE)  
📍 17:00 – 18:00 (PERTH)

## **A New Era in Post-Transplant Cytomegalovirus (CMV) Management:**

**Introducing LIVTENCITY®  
(maribavir)**

### **Virtual discussion forum**

Join global experts Prof. Germaine Wong, Prof. David Ritchie and Dr. Tina Marinelli as they offer a comprehensive perspective on post-transplant CMV management.

### **Meeting overview**

- Multidisciplinary insights from transplant experts
- Exploring clinical decision-making in complex CMV cases – how our experts are integrating new antiviral options into practice
- Key findings from the SOLSTICE study

#### **For more information contact:**

David Young  
David.young1@takeda.com  
+61 407866485



#### **CHAIR**

**Prof. Germaine Wong**  
Director of the Western  
Renal Service  
Westmead Hospital



#### **SPEAKER**

**Prof. David Ritchie**  
Acting Director Dept. of  
Clinical Haematology  
Royal Melbourne  
Hospital



#### **SPEAKER**

**Dr Tina Marinelli**  
Infectious Diseases  
Staff Specialist  
Royal Prince Alfred  
Hospital

**CLICK HERE TO  
REGISTER NOW!**



**PBS Information:** This product is listed on the PBS. Authority required. Refer to PBS Schedule for full authority information.

Please review full Product Information before prescribing. Product Information is available from Takeda Pharmaceuticals Australia Pty Ltd. Phone: 1800 012 612. Email: [medinfoAPAC@takeda.com](mailto:medinfoAPAC@takeda.com) or by [clicking here](#).

▼ This medicinal product is subject to additional monitoring in Australia. This will allow quick identification of new safety information. Healthcare professionals are asked to report any suspected adverse events at [www.tga.gov.au/reporting-problems](http://www.tga.gov.au/reporting-problems)

LIVTENCITY▼ (maribavir) is indicated for the treatment of adults with posttransplant cytomegalovirus (CMV) infection and disease resistant, refractory or intolerant to one or more prior therapies (see 4.3 Contraindications and, 4.4 Special Warnings and Precautions for Use of the full LIVTENCITY Product Information)(1).

**References:** 1. LIVTENCITY. Approved Product Information.

**Disclaimer:** This meeting is for Healthcare Professionals only. Personal information collected from you by Takeda when you register for this meeting will be used for communication about the meetings only. Your personal information will be treated in accordance with applicable laws and in accordance with Takeda policies. For more information you can check Takeda's privacy notice at [www.takeda.com/privacy-notice/](http://www.takeda.com/privacy-notice/) or contact the Privacy Officer by e-mail at [Privacyoffice@takeda.com](mailto:Privacyoffice@takeda.com) or call +612 8019 4400.

LIVTENCITY® and the LIVTENCITY logo® are registered trademarks of Takeda Pharmaceuticals International AG. TAKEDA® and the TAKEDA logo® are registered trademarks of Takeda Pharmaceutical Company Limited. Takeda Pharmaceuticals Australia Pty Ltd, Sydney, NSW 2000. Tel: 1800 012 612. Email: [medinfoAPAC@takeda.com](mailto:medinfoAPAC@takeda.com) ABN 71 095 610 870. C-APROM/AU/LIV/0027. Date of Preparation: July 2025.